Adenosine for the Management of Neonatal and Pediatric Supraventricular Tachycardia

Contributing Editor: Marcia L. Buck, Pharm.D.; Editorial Board: Kristi N. Hofer, Pharm.D.; Michelle W. McCarthy, Pharm.D.

Disclosures

Pediatr Pharm. 2008;14(8) 

In This Article

Summary

Twenty years of clinical experience have shown that adenosine is a valuable tool in the management of SVT in infants and children. At an initial dose of 0.1 mg/kg, with titration as needed, adenosine is both effective and safe for most patients. Although rare, adenosine can produce severe heart block or asystole. Careful patient evaluation and close monitoring both during and after adenosine administration are necessary to ensure optimal patient response.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....